G02, Kwok Sports Building, The Chinese University of Hong Kong
Hong Kong, Please Select, 999077, China
Location status: Recruiting
NCT Number: NCT07344636
Zone 2 training, a low-intensity endurance exercise performed at approximately 66-80% of VO₂max or near the first ventilatory threshold, has gained popularity for improving aerobic capacity, fat metabolism, and mitochondrial efficiency. It preserves glycogen stores and delays fatigue, making it an essential training method for both athletes and recreational exercisers. Nicotinamide adenine dinucleotide (NAD) is a vital metabolite that regulates cellular energy metabolism and redox homeostasis. It participates in oxidative reactions within the tricarboxylic acid cycle and electron transport chain, sustaining ATP synthesis and mitochondrial efficiency. Exercise influences multiple pathways of NAD metabolism, altering the NAD⁺/NADH ratio and thereby affecting energy production and fatigue resistance. Studies have shown that both aerobic exercise and NAD precursor supplementation (e.g., nicotinamide riboside [NR]) can elevate body NAD levels and enhance mitochondrial function, though findings remain inconsistent due to variations in dosage and participants' characteristics. This study aims to investigate how acute NR supplementation interacts with Zone 2 cycling training in adults. Specifically, it examines the temporal and dose-dependent effects of NR supplementation on metabolic flexibility and exercise performance. The results may clarify the potential synergistic benefits of combining NAD supplementation with low-intensity endurance training to improve aerobic adaptability.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Hong Kong, Please Select, 999077, China
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
600 mg NR
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
Muscle pain scale is a 5-point likert scale ranging from "1- Not at all" to "5- Extreme", with higher value indicating muscle pain.
Time frame: From enrollment to the end of treatment at 4 weeks
Muscle fatigue scale is a 5-point likert scale ranging from "1- Not at all" to "5- Extreme", with higher value indicating muscle fatigue.
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
Time frame: From enrollment to the end of treatment at 4 weeks
This questionnaire includes questions regarding participant's present/past history of diseases and his/her family history of diseases.
Time frame: From enrollment to the end of treatment at 4 weeks
IPAQ is a validated questionnaire to measure the physical activity of participants during the past 7 days. The score will be transformed to metabolic equivalents of tasks per week (METs/week), with higher value indicating greater participation in physical activity.
ZHANG Jiaqi
Other
Temporal and Dose-response Effects of Nicotinamide Riboside Supplementation on Metabolic Flexibility During Zone 2 Training in Adults: a Double-blinded, Randomized, Controlled, Crossover Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07673458
Health Adult Subjects
Langfang, Hebei, China
View Trial DetailsNCT07675590
Autoimmune Diseases, Body Weight
Chula Vista, California, United States
View Trial DetailsNCT07178288
Arm Injuries, Ceroid lipofuscinosis, neuronal 1, infantile
Zarqa, Zarqa Governorate, Jordan
View Trial DetailsNCT07101341
Acute Effects of Exercise in Healthy People, Health Adult Subjects
Valencia, Spain
View Trial Details